IP Library Granted Patent US 8,143,022
Granted Patent B2
US 8,143,022 · App. 11/992,837 · Granted Mar 27, 2012

High production system for infectious hepatitis C virus particle

Assignee: Tokyo Metropolitan Institute of Medical Science
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,143,022
App. No.
11/992,837
Granted
Mar 27, 2012
Kind
B2
Abstract

The present invention relates to a method for producing infectious hepatitis C virus (HCV) particles, comprising a step of introducing an expression vector into a cell that allows HCV proliferation, such expression vector comprising: DNA sequences encoding the 5′ untranslated region, structural proteins, and, if necessary, non-structural proteins of HCV and DNA sequences encoding non-structural proteins and the 3′ untranslated region derived from the HCV JFH1 strain, which are located downstream of a polymerase I promoter; and a DNA fragment containing an RNA polymerase I terminator, which is located further downstream thereof.

Claims (7)

1. A method for producing infectious hepatitis C virus (HCV) particles, comprising the step of introducing the following expression vector i) or ii) into a cell that is selected from the group consisting of Huh7, Huh7.5.1, and HepG2 cells:

i) an expression vector comprising: DNA sequences encoding the 5′ untranslated region, Core protein, E1 protein, E2 protein, p7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, and NS5B protein and the 3′ untranslated region derived from the HCV JFH1 strain, downstream of an RNA polymerase I promoter; and DNA comprising an RNA polymerase I terminator, further downstream thereof; or

ii) an expression vector comprising: DNA sequences encoding the 5′ untranslated region, Core protein, E1 protein, E2 protein, and p7 protein derived from an HCV J6CF strain and DNA sequences encoding NS2, NS3, NS4A, NS4B, NS5A, and NS5B proteins and the 3′ untranslated region derived from the HCV JFH1 strain, downstream of an RNA polymerase I promoter; and DNA containing an RNA polymerase I terminator, further downstream thereof.

2. The method according to claim 1 , wherein said expression vector i) comprises the nucleotide sequence of SEQ ID NO: 27.

3. The method according to claim 1 , wherein said expression vector ii) comprises the nucleotide sequence of SEQ ID NO: 29.

4. The method according to claim 1 , wherein said expression vector i) is introduced into a HepG2 cell.

5. The method according to claim 1 , wherein said expression vector ii) is introduced into a Huh7.5.1 cell.

Assignments (2)
CHANGE OF NAME Recorded Sep 20, 2011
From: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH
To: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
Reel/Frame 026931/0980 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2008
From: TANABE, JUN-ICHI; SONE, SABURO; WAKITA, TAKAJI; ISHII, KOJI; SUZUKI, RYOSUKE; SUZUKI, TETSURO; MIYAMURA, TATSUO
To: JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES; TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH; TORAY INDUSTRIES, INC.
Reel/Frame 020857/0388 →
Priority Claims (1)
JP 2005-287646 · Sep 30, 2005 · national
Continuity (1)
Related Publication 20100035345A1 · Feb 11, 2010